Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00602329
Other study ID # CDR0000580810
Secondary ID UPCC-09205GENENT
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 2006
Est. completion date October 2009

Study information

Verified date April 2020
Source Abramson Cancer Center of the University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This randomized phase II trial is studying how well MRI works in predicting response to combination chemotherapy given together with bevacizumab in treating patients with advanced or metastatic colorectal cancer.


Description:

OBJECTIVES:

Primary

- To determine the alteration of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced or metastatic colorectal cancer after 2 courses of combination chemotherapy comprising oxaliplatin, fluorouracil, and leucovorin (FOLFOX) and bevacizumab at 5 mg/kg vs 10 mg/kg or FOLFOX alone.

Secondary

- To correlate tumor blood flow, as assessed by DCE-MRI, with time to progression in patients receiving bevacizumab at 5mg/kg vs 10mg/kg.

- To correlate vascular proliferation, as measured by DCE-MRI, with markers of endothelial cell proliferation (i.e., CD31, 34, 105; integrin αvß3; phospho-ERK; Ki67; PCNA; and smooth muscle actin).

- To obtain pilot data on whether assays that measure vascular endothelial cell mitogenic stimulation and mitogenic activity may predict response to therapy, time to progression, and overall survival of patients receiving bevacizumab at 5mg/kg vs 10mg/kg.

- To investigate the association of various markers of apoptosis in tumor cells (e.g., MIF, CREB, or HIF-1-alpha expression/polymorphism and others) and tumor vascularity, as assessed by DCE-MRI.

- To correlate markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival.

- To determine serum levels of VEGF prior to the initiation of chemotherapy and then prior to courses 2 and 3 of chemotherapy as potential markers of antiangiogenic activity.

OUTLINE: Patients who are eligible to receive bevacizumab are randomized to 1 of 2 treatment arms. Patients who are ineligible to receive bevacizumab receive FOLFOX alone.

- Arm I: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.

- FOLFOX alone (control): Patients receive FOLFOX as in arm I. All patients undergo dynamic contrast-enhanced MRI at baseline and between courses 2 and 3 (between days 17 and 29) to assess tumor blood flow.

Tumor tissue specimens are obtained from prior colonoscopic biopsy or surgical resection in patients receiving bevacizumab. Tissue specimens are examined by immunohistochemistry to evaluate tumor markers of angiogenesis and apoptosis (e.g., CD31, 34, 105, phospho-ERK, PCNA, Ki67, SMA, and integrin αvß3). Blood specimens are obtained at baseline and prior to courses 2 and 3 (days 15 and 29) to evaluate plasma levels of VEGF.

After completion of study therapy, patients are followed every 2 months for 1 year and then every 3 months thereafter.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date October 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum

- Patients receiving bevacizumab must have tumor tissue available for immunohistochemical analysis

- Formalin-fixed, paraffin-embedded tissue from previous biopsy or surgical resection is sufficient

- Measurable disease, defined by RECIST as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques (i.e., CT or MRI)

- CEA elevation alone is insufficient for study entry

- No known brain metastases

PATIENT CHARACTERISTICS:

Criteria for all patients

- ECOG performance status 0-1

- Life expectancy > 3 months

- Granulocytes = 1,500/mL

- Platelet Count = 100,000/mL

- Creatinine = 1.5 times upper limit of normal (ULN)

- Bilirubin = 1.5 times ULN

- AST = 5 times ULN

- Urine protein:creatinine ratio = 1.0 at screening

- Patients with other prior malignancies are eligible, provided they have been treated with curative intent and have no evidence of recurrence

- Not pregnant or nursing

- Negative pregnancy test

- No contraindications to MRI, including any of the following:

- Hypersensitivity to gadolinium

- Metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI-compatible mechanical and/or electrical device, or metallic fragments

- Severe claustrophobia

Additional criteria for patients receiving bevacizumab:

- No significant traumatic injury within the past 28 days

- No serious nonhealing wounds, ulcers, or bone fractures

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months

- No myocardial infarction, unstable angina, or cerebrovascular accident within the past 6 months

- No clinically significant peripheral vascular disease

- No New York Heart Association class II-IV congestive heart failure

- Patients with pre-existing hypertension should be on a stable antihypertensive regimen with blood pressure = 150/100 mm Hg at study entry

PRIOR CONCURRENT THERAPY:

Criteria for all patients

- Prior adjuvant treatment including oxaliplatin allowed

- No prior bevacizumab

- At least 14 days since prior radiotherapy and recovered

- More than 6 months since prior chemotherapy

- No other concurrent investigational agents

Additional criteria for patients receiving bevacizumab:

- At least 28 days since prior major surgical procedure or open biopsy

- At least 7 days since prior minor surgical procedure (e.g., fine-needle aspirations or core biopsies)

- No anticipation of need for a major surgical procedure during study treatment

- Concurrent oral or parenteral anticoagulation therapy allowed provided dose is stable

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
bevacizumab
Given IV
Drug:
fluorouracil
Given IV
leucovorin calcium
Given IV
oxaliplatin
Given IV

Locations

Country Name City State
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Abramson Cancer Center of the University of Pennsylvania National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value 2 cycles for all subjects
Secondary Analysis of tumor markers of angiogenesis and apoptosis, and the effect of treatment 2 cycles for all subjects
Secondary Correlation of tumor blood flow with time to progression 2 cycles
Secondary Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival 2 cycles for all subjects
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A